Trial Profile
A Multiple-dose, Subject and Investigator Blinded, Placebo-controlled, Parallel Design Study to Assess the Efficacy, Safety and Tolerability of ACZ885(Canakinumab) in Patients With Pulmonary Sarcoidosis
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Apr 2022
Price :
$35
*
At a glance
- Drugs Canakinumab (Primary)
- Indications Pulmonary sarcoidosis
- Focus Therapeutic Use
- Sponsors Novartis Pharmaceuticals
- 02 May 2019 Status changed from active, no longer recruiting to completed.
- 11 Feb 2019 Planned End Date changed from 26 Dec 2018 to 4 Mar 2019.
- 11 Feb 2019 Planned primary completion date changed from 26 Dec 2018 to 4 Mar 2019.